{ "schemaVersion": "deck-intelligence.v1", "id": "019de076-341d-707d-8f10-e094a3d9771c", "slug": "c0c2a81b97260bf20014943df2470872", "title": "Equillium | Investor Presentation Deck | 39 slides", "subtitle": "Equillium · 2023-11", "author": "Equillium", "date": "2023-11-01 00:00:00", "pageCount": 39, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de076-341d-707d-8f10-e094a3d9771c", "slug": "c0c2a81b97260bf20014943df2470872", "title": "Equillium | Investor Presentation Deck | 39 slides", "rawTitle": "Equillium | Investor Presentation Deck | 39 slides", "authorId": "equillium", "authorName": "Equillium", "authorDisplay": "Equillium", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2023-11__equillium__investor-pres__c0c2a81b.pdf", "sourceUrl": "https://www.slidebook.io/company/equillium/presentation/c0c2a81b97260bf20014943df2470872/", "sourceDate": "2023-11-15 00:00:00", "presentationDate": "2023-11-01 00:00:00", "ingestedAt": "2026-04-30 22:15:36.322275+00", "status": "ready", "pageCount": 39, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-11__equillium__investor-pres__c0c2a81b", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 39, "pagesIndexed": 39, "pagesWithImages": 39, "pagesWithMetadata": 39, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 197, "chartCount": 10, "metricSlides": 0, "toolMatches": 10, "documentToolMatches": 0, "frameworkMatches": 12, "arcMatches": 1, "beatMatches": 5, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "evidence": "The deck follows a structure similar to the Sequoia Pitch, with sections on problem, solution, market sizing, traction, and team.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:39:34.297363+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 10, "name": "Problem", "beatId": "2fe5fb17-d355-4c63-904d-8dd7cf9a8933", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The problem is clearly stated on page 10.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 5, "name": "Solution", "beatId": "e7dddfc4-f08d-43c8-aba1-5bea798c5a3e", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution is presented on pages 5-9.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 18, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 18, "name": "Market Size", "beatId": "c2be1031-ac04-43ce-b024-d0e129b5699a", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "Market sizing is discussed on page 18.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 21, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 20, "name": "Traction", "beatId": "17f2549b-60e8-4ea8-b75d-3f3cfbce32a9", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": null, "evidence": "Traction is highlighted on pages 20-21.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 35, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 35, "name": "Team", "beatId": "493482e1-fe58-4e6b-904e-a76e5407321c", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "The team is introduced on page 35.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null, "categoryName": "Vision", "categorySlug": "vision" }, "matchId": "8ce5e68a-8dd1-44fc-a48d-607611baedc4", "evidence": "The golden circle is visible in the executive summary and solution sections.", "position": 0, "objective": "Why Equillium", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:39:34.509369+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 25, "from": 25, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "04b5f862-a1da-427a-9706-844a7a78d8b4", "evidence": "The cost of inaction is implied in the discussion of unmet need.", "position": 1, "objective": "Unmet need in Alopecia Areata", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:39:34.544232+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0d393c49-ef95-44ce-a680-ad7c76450b0a", "evidence": "The slide provides a concise overview of the company and its investment highlights, which is a clear example of an executive summary.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:36:11.761634+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "AIDA Model", "slug": "aida-model", "status": "active", "bestFor": null, "canonId": "019dd956-86fc-773c-813f-d416714b8413", "version": 1, "bodyDocId": null, "description": "Attention, Interest, Desire, Action - classic persuasion sequence", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "a1d86fc4-36e3-435e-80b5-3ce13e4fb6d4", "evidence": "The slide presents a clear call-to-action and a defined response to a problem, which aligns with the AIDA model's (Attention, Interest, Desire, Action) structure.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:36:02.837858+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Call to action", "slug": "call-to-action", "status": "active", "bestFor": null, "canonId": "019dd9e1-4bbb-702a-9ead-82daf188bb7c", "version": 1, "bodyDocId": null, "description": "Explicit prescription of what the audience should do next.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ff7e4667-fe39-4738-a0bc-345674cdcd70", "evidence": "The slide includes a clear call-to-action with 'Ono Pharmaceutical: High Value Strategic Partnership'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:36:02.882784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Analytical method", "slug": "analytical-method", "status": "active", "bestFor": null, "canonId": "b42c4911-7946-49b5-951c-5f3d23f4e2bd", "version": 1, "bodyDocId": null, "description": "Diagnostic / structuring methods (5-whys, fishbone, issue tree, hypothesis-driven).", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c0f47ab8-9937-4a2a-8e72-4088687e07db", "evidence": "The slide discusses the role of cytokines in immune responses and their validation as drug targets, which involves an analytical approach.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:36:03.020931+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "d0886153-ec9f-4d34-b843-c0d5d37da3d5", "evidence": "The slide presents a clear problem statement, highlighting the challenges in targeting cytokine signaling.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:36:03.112256+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Before-After-Bridge", "slug": "before-after-bridge", "status": "active", "bestFor": null, "canonId": "019dd956-8604-7188-883f-42370288ad05", "version": 1, "bodyDocId": null, "description": "Narrative structure: Paint the before, show the after, explain the bridge", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "b2af77ee-52be-4c5c-b7fe-1286b70a6a78", "evidence": "image/photo: Before and after clinical photos showing skin improvement at Week 1 vs Week 16", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:39:32.570207+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Data Story Arc", "slug": "data-story-arc", "status": "active", "bestFor": null, "canonId": "019dd956-9c30-728e-b974-d3fb123dcf5a", "version": 1, "bodyDocId": null, "description": "Context → Conflict → Insight → Implication structure for data narratives", "familyLabel": null, "categoryName": "Loop", "categorySlug": "loop" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "03733fe1-99ca-493b-a9b8-256bd836b992", "evidence": "Favorable safety and tolerability demonstrated in 93 subjects across populations with compelling clinical activity observed in CTCL patients", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:39:32.610232+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "45af66c1-ca95-454a-921b-b72bfbae162b", "evidence": "Biological pathway from healthy epithelium to cell death via IL-15/IL-21", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:36:13.085197+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "SCQA Framework", "slug": "scqa-framework", "status": "active", "bestFor": null, "canonId": "019dd956-7bcb-763f-bdf6-1dfedf3bd36c", "version": 1, "bodyDocId": "019df22a-a0b0-719e-937e-2ac31e53d32c", "description": "Situation, Complication, Question, Answer - structured problem framing", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "07f938dd-509c-4c83-9de5-37f99c94325a", "evidence": "Approaches to Treating Celiac Disease: gluten modification, restore gut barrier function, promote immune tolerance, reduce inflammation (IL-15/IL-21)", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:36:13.215947+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Slide recipe: Closing ask", "slug": "closing-ask-slide", "status": "active", "bestFor": null, "canonId": "019df269-295e-70bc-9ee8-baa90a49922d", "version": 1, "bodyDocId": "019df269-293a-7523-9bb5-2692a9047168", "description": "The last slide the reader sees. Treat it as a single design moment —", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "3a1ed35c-9f03-489e-bd4c-a915de6fc377", "evidence": "paragraph/paragraph: www.equilliumbio.com", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:36:13.567183+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "af38a86f-143e-4d11-979a-5fa75998b645", "evidence": "Central logo surrounded by hexagonal strategic pillars", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:00.413+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "frameworkName": "hub-spoke" }, { "matchId": "19439b07-2a0c-404e-99e7-b849c421e5a8", "evidence": "The table uses horizontal bars to represent the progression of drug development across clinical phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:00.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "gantt-chart" }, { "matchId": "68349f55-012b-4f13-9256-d9b8916acd5a", "evidence": "Contrasts two flawed approaches to define the ideal solution.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:23:01.032+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "before-after-framing" }, { "matchId": "c95681ba-7d6a-40a9-a1e8-890cabe97ac5", "evidence": "Central core 'Drug Products' surrounded by supporting technological pillars.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:01.173+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "hub-spoke" }, { "matchId": "e33604c3-d1c7-491f-b487-29fd199c4438", "evidence": "Visual representation of shared signaling components converging on a central receptor type", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:23:02.733+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "hub-spoke" }, { "matchId": "37eb20e2-864a-4832-96ca-6f10ded6c616", "evidence": "Compares three distinct therapeutic modalities across mechanism and outcome", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:01.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "comparison_frame" }, { "matchId": "4b0c46ba-02d8-4bcc-af78-19eeac821f67", "evidence": "The diagram depicts a self-reinforcing cycle of immune activity.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:23:05.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "frameworkName": "flywheel" }, { "matchId": "08c5549c-3727-4542-8772-197a37e382ae", "evidence": "Visual comparison of hair growth over time (Day 0 to 21) for two different treatments.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:02.843+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "before-after-framing" }, { "matchId": "0e0c814a-3d66-4b65-b5e0-752cfdfc0aa8", "evidence": "Study design timeline", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:23:02.411+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "frameworkName": "process" }, { "matchId": "26a6adcb-c82b-470b-a80f-6a49eab61bdf", "evidence": "Sequential flow of clinical trial phases", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:23:04.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "frameworkName": "process" }, { "matchId": "6b543cfe-ee0a-4429-861d-9a615156728d", "evidence": "Timeline visualization of overlapping patent and exclusivity periods", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:03.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "gantt-chart" }, { "matchId": "90d482f5-91f1-44d5-a093-41850816053a", "evidence": "The slide presents a timeline of clinical milestones for multiple programs.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 11:23:04.915+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "frameworkName": "gantt-chart" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/rHuglB_y5peJUoiw62zgcolMAkIo_kVrUKRGSNl0sEk/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMGMyYTgxYjk3MjYwYmYyMDAxNDk0M2RmMjQ3MDg3Mi9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 18, "componentCount": 4, "textChars": 44, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:22:59.211+00", "seconds": 2.436, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/1", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-1", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.71, "w": 0.35, "x": 0.07, "y": 0.145 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:22:59.211+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "75a7ab30-2816-4ddb-9f6b-6d0cc3b11781", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.285, "x": 0.497, "y": 0.188 }, "kind": "image", "text": "equillium", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:22:59.211+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fdccad93-b4f8-44f0-9e66-f97daac33e36", "parentComponentId": null }, { "bbox": { "h": 0.024, "w": 0.125, "x": 0.5, "y": 0.738 }, "kind": "paragraph", "text": "November 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:22:59.211+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1fc75652-cade-424d-8514-599a79d15da8", "parentComponentId": null }, { "bbox": { "h": 0.088, "w": 0.255, "x": 0.5, "y": 0.538 }, "kind": "title", "text": "Corporate Presentation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:22:59.211+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2120a10d-1428-4f22-9252-fa39a7cdf879", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/ATKbBqOH-iXwVp7Y2xz5nXh4dJbE4SXrM4tcFUqFfeU/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMGMyYTgxYjk3MjYwYmYyMDAxNDk0M2RmMjQ3MDg3Mi9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/SqtXoLaVPSIL82HjYRXBvGPdWoBmSVb9TAh4Thqxy90/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMGMyYTgxYjk3MjYwYmYyMDAxNDk0M2RmMjQ3MDg3Mi9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/7cwJBDKwrZwwSsZpMZlrEiesk9q4eyzHLH7D7hjwL_g/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMGMyYTgxYjk3MjYwYmYyMDAxNDk0M2RmMjQ3MDg3Mi9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "appendix_disclosure", "block": null, "metadata": { "slideType": "appendix_disclosure", "slideTypeCanon": { "name": "Appendix disclosure", "slug": "appendix_disclosure", "status": "active", "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 4, "textChars": 3264, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:05.087+00", "seconds": 7.962, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/2", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-2", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.105, "w": 0.941, "x": 0.037, "y": 0.808 }, "kind": "disclaimer", "text": "Trademarks\nThis presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM © or ® symbols, but Equillium will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:05.087+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2cdad793-9745-4db1-8dba-b30f06ad6f83", "parentComponentId": null }, { "bbox": { "h": 0.555, "w": 0.463, "x": 0.037, "y": 0.178 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements about Equillium, Inc. (the “Company”). In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements are based on Company management’s current beliefs and expectations. These statements include but are not limited to statements regarding the Company’s business strategy, the Company’s plans to develop and commercialize its product candidates, the safety and efficacy of the Company’s product candidates, the Company’s plans and expected timing with respect to regulatory filings and approvals, size and growth potential of the markets for the Company’s product candidates and cash runway. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company’s forward-looking statements.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:05.087+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "57e81db2-e3d1-4870-82b4-0affb6a0de36", "parentComponentId": null }, { "bbox": { "h": 0.555, "w": 0.463, "x": 0.515, "y": 0.178 }, "kind": "disclaimer", "text": "Actual results or events could differ materially from the plans, intentions and expectations disclosed or implied in the forward-looking statements the Company makes due to the risks and uncertainties inherent in the Company’s business, including without limitation, the risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”). You are cautioned not to place undue reliance on these forward-looking statements, which represent the Company’s views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company has no current intention of doing so except to the extent required by applicable law. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting EDGAR on the SEC web site at http://www.sec.gov and on the Company’s website under the heading “Investors.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:05.087+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4158b33-fd1b-47bf-96bd-9a8aed2de926", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.427, "x": 0.037, "y": 0.075 }, "kind": "title", "text": "Forward-Looking Statements", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:05.087+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fae80634-b149-4a8d-bb93-8f2293583a98", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "title": "Uses a hub-and-spoke diagram to represent the company's strategic pillars.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 28, "componentCount": 4, "textChars": 206, "nDataPoints": 0, "notes": "Uses a hub-and-spoke diagram to represent the company's strategic pillars.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:00.413+00", "seconds": 3.198, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/3", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-3", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.48, "w": 0.48, "x": 0.465, "y": 0.15 }, "kind": "diagram", "text": "Hub-and-spoke diagram showing investment highlights", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.413+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3278d70e-f909-459f-89c1-71b263e42032", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.03, "y": 0.45 }, "kind": "paragraph", "text": "Developing high-impact, novel therapeutics to treat autoimmune and inflammatory disorders", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.413+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0831e274-9268-4bc7-812d-a3c0859dd83c", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.35, "x": 0.03, "y": 0.32 }, "kind": "title", "text": "Leaders in immunobiology", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.413+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f48ac1ae-771e-44f6-9270-2321e9e2f0b5", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Equillium Snapshot & Investment Highlights", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.413+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "85d7bdc6-b447-4a44-9463-359d32a6ae00", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0d393c49-ef95-44ce-a680-ad7c76450b0a", "evidence": "The slide provides a concise overview of the company and its investment highlights, which is a clear example of an executive summary.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:36:11.761634+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "af38a86f-143e-4d11-979a-5fa75998b645", "evidence": "Central logo surrounded by hexagonal strategic pillars", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:00.413+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "frameworkName": "hub-spoke" } ], "arcBeats": [], "loops": [ { "to": 5, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "8ce5e68a-8dd1-44fc-a48d-607611baedc4", "evidence": "The golden circle is visible in the executive summary and solution sections.", "position": 0, "objective": "Why Equillium", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:39:34.509369+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 4, "type": "resolution", "title": "The slide uses a Gantt-style visualization for drug development stages.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 4, "textChars": 242, "nDataPoints": 0, "notes": "The slide uses a Gantt-style visualization for drug development stages.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:00.51+00", "seconds": 3.106, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/4", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-4", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": null, "kind": "framework", "text": "Gantt chart representation of drug development stages", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "68abb7c3-9d8c-4bbb-b9f2-44952c8349be", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.08, "x": 0.68, "y": 0.61 }, "kind": "image", "text": "Ono Pharma and Biocon logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "58779f5f-11e3-4676-b649-19dc036d3749", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.925, "x": 0.037, "y": 0.197 }, "kind": "table", "text": "Pipeline table with columns: Drugs, Indication, Pre-Clinical/Phase 1/2/3, Partners, Anticipated Milestones", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fc83ee74-e5c2-4c9c-b005-34a529084b4a", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.63, "x": 0.037, "y": 0.075 }, "kind": "title", "text": "Diversified Pipeline of First-In-Class Immunology Assets", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "332f7cd4-1ff1-479a-92d3-fcfd9a22a3da", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "19439b07-2a0c-404e-99e7-b849c421e5a8", "evidence": "The table uses horizontal bars to represent the progression of drug development across clinical phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:00.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [ { "to": 5, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "8ce5e68a-8dd1-44fc-a48d-607611baedc4", "evidence": "The golden circle is visible in the executive summary and solution sections.", "position": 0, "objective": "Why Equillium", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:39:34.509369+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "resolution", "title": "This is a section divider or introductory slide for the product solution.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "sparse", "densityScore": 8, "componentCount": 2, "textChars": 97, "nDataPoints": 0, "notes": "This is a section divider or introductory slide for the product solution.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:22:59.543+00", "seconds": 2.019, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/5", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-5", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.12, "x": 0.85, "y": 0.06 }, "kind": "image", "text": "equillium", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:22:59.543+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e95709f8-55d1-45f7-8ef3-a8a020e3b528", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.61, "x": 0.048, "y": 0.445 }, "kind": "title", "text": "Itolizumab First-in-Class immune-modifying mAb targeting the CD6-ALCAM signaling pathway", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:22:59.543+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "05bd8f1e-742a-4f48-bb91-b64d3376c180", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "e7dddfc4-f08d-43c8-aba1-5bea798c5a3e", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution is presented on pages 5-9.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "8ce5e68a-8dd1-44fc-a48d-607611baedc4", "evidence": "The golden circle is visible in the executive summary and solution sections.", "position": 0, "objective": "Why Equillium", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:39:34.509369+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "evidence", "title": "Includes specific financial breakdown of deal value and R&D funding obligations.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 86, "componentCount": 8, "textChars": 957, "nDataPoints": 5, "notes": "Includes specific financial breakdown of deal value and R&D funding obligations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:01.559+00", "seconds": 4.005, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/6", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-6", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 1 }, "kind": "callout", "text": "Equillium receives upfront payment and full funding of itolizumab R&D in exchange for Ono exclusive option to purchase Equillium’s rights to itolizumab", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "32acb958-d735-4c4a-a078-2d98ba6c7bd2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.62, "y": 0.0035 }, "kind": "image", "text": "ONO PHARMACEUTICAL CO.,LTD.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c0a78cfc-fdc0-4cb5-9e22-36b34487b482", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.05, "y": 0.008 }, "kind": "list", "text": "Clinical; Regulatory; First sale", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "333db97f-b806-46bb-bd98-bf0b563ab19b", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.45, "x": 0.05, "y": 0.0055 }, "kind": "list", "text": "Equillium to continue conducting all itolizumab R&D; Ono to fund all R&D expenses from July 1, 2022 through the option period; R&D budget approximately $8M per quarter", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f6b1858e-fea2-4b8e-88d6-dbe8ca5d5682", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.62, "y": 0.0045 }, "kind": "paragraph", "text": "Option period expires three months following delivery of: topline data from the EQUALISE study in lupus nephritis, and interim data from the EQUATOR study in acute GVHD", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eebe6717-7683-488c-abed-c864b8c27eb9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.0092 }, "kind": "source-note", "text": "*Option exercise payment of ¥5.0B is based in JPY and subject to currency exchange rate at the time of payment (USD amount above is based on the exchange rate as of November 3, 2023); milestone payments and R&D reimbursement are based in USD.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "64a36343-de71-4a00-9d97-24f94edabdce", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.45, "x": 0.05, "y": 0.0035 }, "kind": "table", "text": "Upfront payment: $26.4M; Option exercise payment: $33.3M*; Milestone payments: $101.4M; Total potential value: $162.9M", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "KPI table", "slug": "kpi", "status": "active", "canonId": "019de52d-0324-7799-a84e-d0885a8ad400", "version": 1, "description": null }, "framework": null }, "subkind": "kpi", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "06162038-38ac-4df4-9caa-0dcacddc75a4", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.75, "x": 0.05, "y": 0.07 }, "kind": "title", "text": "Ono Pharmaceutical: High Value Strategic Partnership", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cd63abc8-286b-4dfa-a853-d0177fc5200d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "AIDA Model", "slug": "aida-model", "status": "active", "bestFor": null, "canonId": "019dd956-86fc-773c-813f-d416714b8413", "version": 1, "bodyDocId": null, "description": "Attention, Interest, Desire, Action - classic persuasion sequence", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "a1d86fc4-36e3-435e-80b5-3ce13e4fb6d4", "evidence": "The slide presents a clear call-to-action and a defined response to a problem, which aligns with the AIDA model's (Attention, Interest, Desire, Action) structure.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:36:02.837858+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Call to action", "slug": "call-to-action", "status": "active", "bestFor": null, "canonId": "019dd9e1-4bbb-702a-9ead-82daf188bb7c", "version": 1, "bodyDocId": null, "description": "Explicit prescription of what the audience should do next.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ff7e4667-fe39-4738-a0bc-345674cdcd70", "evidence": "The slide includes a clear call-to-action with 'Ono Pharmaceutical: High Value Strategic Partnership'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:36:02.882784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "e7dddfc4-f08d-43c8-aba1-5bea798c5a3e", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution is presented on pages 5-9.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 7, "type": "resolution", "title": "The slide uses a side-by-side comparison structure to detail trial status and upcoming milestones for two distinct clinical programs.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 439, "nDataPoints": 1, "notes": "The slide uses a side-by-side comparison structure to detail trial status and upcoming milestones for two distinct clinical programs.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:00.179+00", "seconds": 2.405, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/7", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-7", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.45, "x": 0.04, "y": 0.38 }, "kind": "list", "text": "EQUALISE Phase 1b in lupus nephritis: Fully enrolled, Open-label study, interim data showed meaningful response. Milestone: Topline data expected early 2024.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.179+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "04a9328c-3695-46fb-a0ec-d708e0e61d09", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.45, "x": 0.52, "y": 0.38 }, "kind": "list", "text": "EQUATOR Pivotal Phase 3 in acute GVHD: Enrolling (n=200), Randomized controlled study (1:1), Phase 1B showed high response rates. Milestone: Interim Review @ 100 patients expected 2024.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.179+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a5c304f-9afb-4c1f-898b-23568c5f5818", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.68, "x": 0.04, "y": 0.21 }, "kind": "title", "text": "Itolizumab: Two Data Deliverables Expected in 2024", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.179+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54e216e9-bbaa-4a66-acdc-74095f49094a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.75, "x": 0.04, "y": 0.07 }, "kind": "title", "text": "Driving Development Towards Ono Option Decision", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.179+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "38219b4c-0426-45d9-90bc-04f3d7e4bac6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "e7dddfc4-f08d-43c8-aba1-5bea798c5a3e", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution is presented on pages 5-9.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 8, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 6, "componentCount": 2, "textChars": 57, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:02.727+00", "seconds": 4.886, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/8", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-8", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.1, "x": 0.85, "y": 0.05 }, "kind": "image", "text": "equillium", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.727+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "df5026db-4b87-45eb-b5cc-4908ebaae619", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.45, "x": 0.048, "y": 0.445 }, "kind": "title", "text": "Multi-Cytokine Platform & Therapeutic Candidates", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.727+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "29ecede5-b5af-462e-b4df-c8c6e687facd", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "e7dddfc4-f08d-43c8-aba1-5bea798c5a3e", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution is presented on pages 5-9.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 9, "type": "setup", "title": "Includes a diagram illustrating cytokine-receptor binding and downstream signaling.", "function": "establish_context", "rawType": "context", "block": null, "metadata": { "slideType": "context", "slideTypeCanon": { "name": "Context (pitchdeck)", "slug": "context", "status": "active", "canonId": "019de52d-1094-779e-9590-e4603e6a191c", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 6, "textChars": 712, "nDataPoints": 0, "notes": "Includes a diagram illustrating cytokine-receptor binding and downstream signaling.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:01.056+00", "seconds": 3.132, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/9", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-9", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.25, "x": 0.68, "y": 0.35 }, "kind": "image", "text": "Diagram of cytokine binding to receptors and triggering downstream signal", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.056+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f137c623-e706-4eb3-b759-664a89b8a926", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.036, "y": 0.375 }, "kind": "list", "text": "Cytokines can exhibit overlapping or synergistic biological activities", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.056+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "71d1c231-d246-432a-9be0-8fe25cae66df", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.7, "x": 0.036, "y": 0.48 }, "kind": "list", "text": "Most drugs used to treat autoimmune and/or inflammatory diseases modulate cytokines by either: 1. Directly neutralizing cytokine binding to upstream receptors, such as anti-TNF 2. Indirectly inhibiting downstream cytokine signaling pathways, such as JAK inhibitors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.056+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eaf5793a-8628-41a1-9d5c-05f7b4bb9ee4", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.036, "y": 0.73 }, "kind": "list", "text": "Interleukins (IL) are a type of cytokine that play essential roles in the activation, proliferation and function of immune cells", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.056+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f8b54479-dc65-48bc-b15e-7c0cb7c72c50", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.75, "x": 0.036, "y": 0.21 }, "kind": "paragraph", "text": "Cytokines are small signaling proteins with essential roles in immune responses, but when not properly regulated they are key disease drivers", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.056+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "da0f576d-e271-4413-88f3-2c294c2b271b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.45, "x": 0.036, "y": 0.075 }, "kind": "title", "text": "Cytokines are Validated Drug Targets", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.056+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9adabf72-9622-4845-a254-c01b665ad7b9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Analytical method", "slug": "analytical-method", "status": "active", "bestFor": null, "canonId": "b42c4911-7946-49b5-951c-5f3d23f4e2bd", "version": 1, "bodyDocId": null, "description": "Diagnostic / structuring methods (5-whys, fishbone, issue tree, hypothesis-driven).", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c0f47ab8-9937-4a2a-8e72-4088687e07db", "evidence": "The slide discusses the role of cytokines in immune responses and their validation as drug targets, which involves an analytical approach.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:36:03.020931+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "e7dddfc4-f08d-43c8-aba1-5bea798c5a3e", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution is presented on pages 5-9.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 10, "type": "tension", "title": "Uses a visual comparison framework to illustrate the 'Goldilocks' problem in drug development.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 5, "textChars": 450, "nDataPoints": 1, "notes": "Uses a visual comparison framework to illustrate the 'Goldilocks' problem in drug development.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:01.032+00", "seconds": 3.104, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/10", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-10", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.25, "x": 0.68, "y": 0.035 }, "kind": "callout", "text": "Inhibiting the right combination of cytokines is key for optimal therapeutic effect, balancing both potent activity and potential toxicities", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.032+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3c7501a-5da5-4553-9528-796a0fd14b7a", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.52, "x": 0.12, "y": 0.25 }, "kind": "image", "text": "Diagram showing mAb inhibiting one cytokine vs JAK inhibitor inhibiting 50+ cytokines", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.032+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "32471d8d-a261-4ee2-b86b-c440cf59c00d", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.11, "y": 0.085 }, "kind": "paragraph", "text": "Inhibition too Narrow: Other Cytokines Involved, leads to insufficient activity", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.032+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bdcfe51b-c122-4cd6-81be-b26ae6fffb94", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.35, "y": 0.85 }, "kind": "paragraph", "text": "Inhibition too Broad: Non-selective cytokine targeting leads to broad immunosuppression and safety risks", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.032+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ffaf4d9a-b635-4553-8c62-28bdb919daaf", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.45, "x": 0.04, "y": 0.07 }, "kind": "title", "text": "Challenges in Targeting Cytokine Signaling", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.032+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b287d4bf-af26-441b-bb25-0990661e2eb3", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "d0886153-ec9f-4d34-b843-c0d5d37da3d5", "evidence": "The slide presents a clear problem statement, highlighting the challenges in targeting cytokine signaling.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:36:03.112256+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "68349f55-012b-4f13-9256-d9b8916acd5a", "evidence": "Contrasts two flawed approaches to define the ideal solution.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:23:01.032+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "before-after-framing" } ], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Problem", "beatId": "2fe5fb17-d355-4c63-904d-8dd7cf9a8933", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The problem is clearly stated on page 10.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 11, "type": "resolution", "title": "The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 45, "componentCount": 4, "textChars": 552, "nDataPoints": 0, "notes": "The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:01.173+00", "seconds": 3.082, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/11", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-11", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.13, "w": 0.926, "x": 0.037, "y": 0.197 }, "kind": "callout", "text": "Modular platform generates products that modulate the natural biological redundancy or synergy of cytokines affording greater therapeutic benefit", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.173+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "99455a71-c093-4801-9837-1b75b3e5d328", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.32, "x": 0.05, "y": 0.365 }, "kind": "diagram", "text": "Drug Products surrounded by Validated Disease Targets, Computational Biology, In-silico design, Protein Engineering, Structure Activity Relationships, Functional Fusions", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.173+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f12ce07c-6fde-4645-b3ba-370677d9d119", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.58, "x": 0.39, "y": 0.46 }, "kind": "list", "text": "Technology originating from the National Institutes of Health; Uniquely targets upstream shared receptors; Intravenous, subcutaneous and oral delivery; Products can be flexibly modified; Broad IP portfolio", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.173+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "62bbc0e5-91f8-4392-9cfe-ccf6754001d3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.47, "x": 0.037, "y": 0.075 }, "kind": "title", "text": "Multi-Cytokine Inhibitor Platform", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.173+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c8a14340-da02-4552-9a9a-698752be4f29", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "c95681ba-7d6a-40a9-a1e8-890cabe97ac5", "evidence": "Central core 'Drug Products' surrounded by supporting technological pillars.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:01.173+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "hub-spoke" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 12, "type": "resolution", "title": "The slide uses a hub-and-spoke visual metaphor to explain the shared signaling mechanism of the γC receptor family.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "sparse", "densityScore": 24, "componentCount": 3, "textChars": 282, "nDataPoints": 0, "notes": "The slide uses a hub-and-spoke visual metaphor to explain the shared signaling mechanism of the γC receptor family.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:02.733+00", "seconds": 4.55, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/12", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-12", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "callout", "text": "Cytokines of the γC receptor are critical regulators of immune responses, thus, making it an attractive drug target for modulating T, NK and B cells", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.733+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fb3f07cd-351a-4de9-b498-407040f7739b", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.9, "x": 0.05, "y": 0.35 }, "kind": "diagram", "text": "Biological signaling diagram showing six receptor complexes sharing a common γ subunit", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.733+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "955170b1-15da-4a83-8ec1-106150178dc3", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "γC Receptor: A Key Shared Cytokine Signaling Hub", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.733+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "82381c6a-56c6-4b25-98a0-16fc854e214f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "e33604c3-d1c7-491f-b487-29fd199c4438", "evidence": "Visual representation of shared signaling components converging on a central receptor type", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:23:02.733+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "hub-spoke" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 13, "type": "resolution", "title": "The slide uses a process diagram to show the transition from native cytokine sequences to a proprietary composite sequence, resulting in an engineered inhibitor", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 5, "textChars": 297, "nDataPoints": 0, "notes": "The slide uses a process diagram to show the transition from native cytokine sequences to a proprietary composite sequence, resulting in an engineered inhibitor.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:00.649+00", "seconds": 2.39, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/13", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-13", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.28, "x": 0.39, "y": 0.17 }, "kind": "chart", "text": "Cytokine D-Helices sequence alignment", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Heatmap", "slug": "heatmap", "status": "active", "canonId": "019de52d-00cd-71ee-bf36-233b7817c304", "version": 1, "description": null }, "framework": null }, "subkind": "heatmap", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.649+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6b73ee7f-45a7-4acb-b482-18f645450546", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.35, "x": 0.03, "y": 0.17 }, "kind": "diagram", "text": "Cytokine-Receptor Complex and Helix interaction", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.649+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "09ec1bef-b6dc-4fb2-ae3c-09ead71043b9", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.25, "x": 0.72, "y": 0.17 }, "kind": "list", "text": "PK extension strategies, Oral delivery, Multi-specific molecules", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.649+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d4f16009-ca51-4e67-8e03-5aa3abaf3812", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.03, "y": 0.73 }, "kind": "paragraph", "text": "Helices A & C interact with the private receptor, while helix D interacts with shared receptor", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.649+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b555f000-6347-42bf-bd56-c75eacc67f56", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.75, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Generation of Selective Multi-Cytokine Inhibitors (MCi)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.649+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f9a5f842-e403-412c-acf1-273293c839ca", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 14, "type": "resolution", "title": "The slide uses a biological mechanism diagram to illustrate how the inhibitor selectively targets specific cytokines (A, D, F) while leaving others unaffected.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 49, "componentCount": 5, "textChars": 434, "nDataPoints": 0, "notes": "The slide uses a biological mechanism diagram to illustrate how the inhibitor selectively targets specific cytokines (A, D, F) while leaving others unaffected.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:01.566+00", "seconds": 3.185, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/14", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-14", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.3, "x": 0.66, "y": 0.22 }, "kind": "chart", "text": "Selective inhibition of cytokines A, D & F", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.566+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8167d6d4-9ed6-464d-bbd2-5f1571f815ed", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.35, "x": 0.05, "y": 0.2 }, "kind": "image", "text": "Diagram showing cytokine binding to private and shared receptors", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.566+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7efefc7e-608b-43d2-9826-07004c87e8a4", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.05, "y": 0.74 }, "kind": "paragraph", "text": "Cytokines first bind to private receptor with high affinity, then transiently dimerize with the γc shared receptor at lower affinity that leads to signaling", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.566+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0ca0316e-eb73-4a37-8461-58a312f202d8", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.28, "x": 0.68, "y": 0.74 }, "kind": "paragraph", "text": "Multi-cytokine inhibitor binds to γc receptor and selectively blocks signaling of only selected cytokines e.g., A, D & F", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.566+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5a5f7c0-1c8a-4933-9e4b-e5cafa464695", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "MCi MoA: Disrupting Assembly of the Receptor Complex", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.566+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2e2f7e2a-10c1-4103-ac26-86f3db0f5ce6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 15, "type": "setup", "title": "The slide uses a visual mechanism to show how different inhibitors interact with cell signaling pathways.", "function": "present_solution", "rawType": "unfair_advantage", "block": null, "metadata": { "slideType": "unfair_advantage", "slideTypeCanon": { "name": "Unfair advantage", "slug": "unfair_advantage", "status": "active", "canonId": "019de52d-0f56-744f-8bb4-c8a8cca240d6", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 35, "componentCount": 4, "textChars": 336, "nDataPoints": 0, "notes": "The slide uses a visual mechanism to show how different inhibitors interact with cell signaling pathways.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:01.612+00", "seconds": 2.929, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/15", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-15", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.85, "x": 0.036, "y": 0.205 }, "kind": "callout", "text": "Addressing limitations of single-target biologics and broadly immunosuppressive kinase inhibitors by selectively inhibiting only those cytokines driving disease", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5230d405-7cd5-4bc3-a2dc-6b2be0138485", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.6, "x": 0.036, "y": 0.35 }, "kind": "diagram", "text": "Comparison of mAb, JAK inhibitor, and MCi mechanisms", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb4c7578-257e-4f7a-a447-f5fbaa8776ec", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.28, "x": 0.68, "y": 0.43 }, "kind": "list", "text": "Targets undruggable sites; Optimized targeting; Increased selectivity; Greater potency", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18e634e3-040f-4186-a8d0-b542ce776f94", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.036, "y": 0.078 }, "kind": "title", "text": "The Multi-Cytokine Inhibitor Advantage", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "746eb8f2-527d-4877-a3a1-d522afbe0792", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "37eb20e2-864a-4832-96ca-6f10ded6c616", "evidence": "Compares three distinct therapeutic modalities across mechanism and outcome", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:01.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "comparison_frame" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 16, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 1, "textChars": 62, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:00.878+00", "seconds": 2.136, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/16", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-16", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.236, "w": 0.468, "x": 0.048, "y": 0.444 }, "kind": "title", "text": "EQ101 First-in-Class Tri-specific Inhibitor of IL-2/IL-9/IL-15", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:00.878+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af2a2330-8e03-4581-97dd-ae84c652f9a4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 17, "type": "resolution", "title": "The slide uses a four-column structure to explain the target, the molecule, the preclinical results, and the clinical results.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 7, "textChars": 1126, "nDataPoints": 1, "notes": "The slide uses a four-column structure to explain the target, the molecule, the preclinical results, and the clinical results.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:02.285+00", "seconds": 3.255, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/17", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-17", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.11, "w": 0.94, "x": 0.03, "y": 0.18 }, "kind": "callout", "text": "Inhibition of the key cytokines IL-2, IL-9 and IL-15 by EQ101 translates from preclinical models into humans", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "48e90daa-8056-4cbd-a489-cea08a96b04f", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.22, "x": 0.03, "y": 0.54 }, "kind": "list", "text": "IL-2 & IL-15 are important to CD8 and NK cell biology, IL-9 contributes to inflammation in the skin. Important to inhibit both IL-2 and IL-15 due to redundancy in signaling on cytotoxic CD8 T cells", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "51005f87-3823-4cb2-8c81-93681eecd121", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.22, "x": 0.27, "y": 0.54 }, "kind": "list", "text": "PEGylated peptide (based on the D-helix) selectively inhibiting IL-2, IL-9 & IL-15 signaling. Administered as a low volume intravenous push, with a sub-cutaneous formulation in development", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5ea71c4d-d7ce-4f8f-8807-08eab035cf7c", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.22, "x": 0.51, "y": 0.54 }, "kind": "list", "text": "As effective as ruxolitinib in inhibiting multiple lymphoproliferative or leukemic T-cell lines. More effective than ruxolitinib in mouse model of immune-mediated hair loss / alopecia areata", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a462a4e8-4116-4955-9e1f-110d69222489", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.22, "x": 0.75, "y": 0.54 }, "kind": "list", "text": "Significant clinical experience in >100 subjects, demonstrated favorable safety and tolerability. Positive proof-of-concept achieved in cutaneous T cell lymphoma patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff64ce61-4612-4d32-b099-d1227af26e87", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.65, "x": 0.12, "y": 0.94 }, "kind": "source-note", "text": "1) Nata et al., J. Biol. Chem., 2015; 2) Massoud et al., PNAS, 2015; 3) Wang et al., Leukemia, 2018; 4) Azimi et al., AHRS, Orlando, Florida, 2018 5) Frohna et al., J. Clin. Pharm., 2019 6) Querfeld et al., Blood, 2019", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "76b3648d-68dc-473c-a5f9-275927e981aa", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "EQ101: A First-in-Class Tri-Specific Cytokine Inhibitor", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "267e00a5-c74c-4e22-b4e0-237b3250a8ea", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 18, "type": "resolution", "title": "The slide uses a column-based layout to compare four distinct disease indications.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 7, "textChars": 919, "nDataPoints": 4, "notes": "The slide uses a column-based layout to compare four distinct disease indications.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:02.606+00", "seconds": 3.301, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/18", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-18", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 0.17 }, "kind": "callout", "text": "Multi-Billion dollar market opportunity for EQ101 in medical dermatology. Large need exists for safe and effective therapies", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.606+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "239af9d8-1b0f-4246-b0ad-a14b233bc4ce", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.2, "x": 0.04, "y": 0.35 }, "kind": "list", "text": "Cutaneous T cell Lymphoma: 24,000 adult US Patients; PoC Achieved, Phase 2/3 Ready, Open IND, Unmet need for safe and effective therapies", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.606+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3c0f61dc-9248-4427-95fb-9ba03ad320bf", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.2, "x": 0.72, "y": 0.35 }, "kind": "list", "text": "Atopic Dermatitis: 6.6M US moderate-severe Patients; Future Opportunity, 3 FDA approved JAKi, Large refractory population in need of safe treatment alternatives", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.606+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bf4ab133-32ca-4fcb-a322-1e4a3474abc3", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.2, "x": 0.49, "y": 0.35 }, "kind": "list", "text": "Vitiligo: 1.5M+ US Patients; Future Opportunity, Only one FDA approval: JAKi, Late-stage Industry pipeline predominantly JAKi", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.606+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d25b0622-d0d3-414d-b644-08e2b8547772", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.2, "x": 0.26, "y": 0.35 }, "kind": "list", "text": "Alopecia Areata: 250,000 US moderate-severe Patients; Phase 2 Study ongoing, Only two FDA approvals: JAKi, Late-stage Industry pipeline predominantly JAKi", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.606+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f98231d2-87d9-46c8-9904-51322cbe222b", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.6, "x": 0.12, "y": 0.94 }, "kind": "source-note", "text": "1) Kx Advisors 2) Benigno, Clin Cosmet Investig Dermatol, 2020 3) Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020 4) Chiesa Fuxench ZC, J Invest Dermatol. 2019", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.606+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8baf1b51-b37e-4d81-85cc-701ec3e580fb", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.04, "y": 0.07 }, "kind": "title", "text": "EQ101: Valuable Medical Dermatology Franchise", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.606+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ef3f9db2-b614-4d28-95cc-6368a981d5fa", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 18, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 18, "name": "Market Size", "beatId": "c2be1031-ac04-43ce-b024-d0e129b5699a", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "Market sizing is discussed on page 18.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 19, "type": "resolution", "title": "The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 49, "componentCount": 5, "textChars": 437, "nDataPoints": 0, "notes": "The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:02.607+00", "seconds": 3.302, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/19", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-19", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.94, "x": 0.03, "y": 0.0011799999999999998 }, "kind": "callout", "text": "JAKi suppression of cytokine signaling is incomplete, while EQ101 inhibits the multiple downstream pathways for complete suppression of cytokine signaling", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.607+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0289a04-dd8e-4ee2-886b-773d9b2cd8f2", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.75, "x": 0.2, "y": 0.0044 }, "kind": "chart", "text": "Western blot data comparing pSTAT, pERK, and pPI3K levels", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.607+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d28aae2-4e44-4307-8cd4-8122d29bfe24", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.9, "x": 0.05, "y": 0.0044 }, "kind": "image", "text": "Diagrams showing IL-2 receptor signaling inhibition by Ruxolitinib vs EQ101", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.607+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f302dd34-e83f-437c-aa85-ebb7349f6d75", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.4, "x": 0.12, "y": 0.96 }, "kind": "source-note", "text": "In-house data and Frohna et al., Alopecia Areata Research Summit, New York, New York, 2018", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.607+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b1b03457-388f-43b8-8c5c-1fadf5dee5f6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.94, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "EQ101: More Complete Downstream Signal Inhibition Versus JAKi", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.607+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aadcbbee-d92a-4519-b132-49233f550002", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 20, "type": "evidence", "title": "Includes before/after clinical photos and a comparative table against Mogamulizumab.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 82, "componentCount": 7, "textChars": 1028, "nDataPoints": 6, "notes": "Includes before/after clinical photos and a comparative table against Mogamulizumab.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:03.401+00", "seconds": 4.07, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/20", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-20", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.09, "w": 0.92, "x": 0.04, "y": 0.18 }, "kind": "callout", "text": "Favorable safety and tolerability demonstrated in 93 subjects across populations with compelling clinical activity observed in CTCL patients", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.401+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5f7295c-bd40-4511-81fe-0041ee82f509", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.5, "x": 0.46, "y": 0.64 }, "kind": "image", "text": "Before and after clinical photos showing skin improvement at Week 1 vs Week 16", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.401+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5bda0e99-62aa-4af1-aafb-b1e0c46529a1", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.4, "x": 0.04, "y": 0.45 }, "kind": "list", "text": "Heavily pre-treated, refractory patient population (median of 5 prior systemic treatments)\nDose escalation (0.5, 1, 2, 4mg/kg) with 4-week treatment/assessment period (n=30) followed by 12+ week extension (n=19)\nNo drug related SAEs, no DLTs and no clinically significant laboratory abnormalities\nDose-dependent PK/PD correlated with improved skin scores (mSWAT)\n2mg/kg was selected dose for study expansion and extension", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.401+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "898ff745-78db-4370-94af-9ac139877f4e", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.4, "x": 0.04, "y": 0.9 }, "kind": "source-note", "text": "1) Kim et al., Lancet Oncol., 2018. 2) Querfeld et al., Blood, 2019. mSWAT = modified severity-weighted assessment CTCL = Cutaneous T cell Lymphoma", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.401+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f7c578e-d57d-4da2-8a9c-6e70fc2364b3", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.5, "x": 0.46, "y": 0.345 }, "kind": "table", "text": "Response Rate in Stage IB/II Patients; MAVORIC Phase 3 Trial; EQ101 Phase 1/2; Mogamulizumab (n=68); EQ101 (n=19); 27.9%; 42.1%", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.401+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ad3c1cf-0e54-4c7c-812e-a320937dfaaa", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.87, "x": 0.04, "y": 0.07 }, "kind": "title", "text": "EQ101: Clinically Validated in Severe Dermatological Disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.401+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0272fcce-3eaf-4646-954b-af37d50f7c7d", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.4, "x": 0.04, "y": 0.345 }, "kind": "title", "text": "Phase 1/2 MAD study in Cutaneous T Cell Lymphoma (n=30)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.401+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "070566f0-5dce-4a98-9dcf-ee0a4da8406a", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Before-After-Bridge", "slug": "before-after-bridge", "status": "active", "bestFor": null, "canonId": "019dd956-8604-7188-883f-42370288ad05", "version": 1, "bodyDocId": null, "description": "Narrative structure: Paint the before, show the after, explain the bridge", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "b2af77ee-52be-4c5c-b7fe-1286b70a6a78", "evidence": "image/photo: Before and after clinical photos showing skin improvement at Week 1 vs Week 16", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:39:32.570207+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Data Story Arc", "slug": "data-story-arc", "status": "active", "bestFor": null, "canonId": "019dd956-9c30-728e-b974-d3fb123dcf5a", "version": 1, "bodyDocId": null, "description": "Context → Conflict → Insight → Implication structure for data narratives", "familyLabel": null, "categoryName": "Loop", "categorySlug": "loop" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "03733fe1-99ca-493b-a9b8-256bd836b992", "evidence": "Favorable safety and tolerability demonstrated in 93 subjects across populations with compelling clinical activity observed in CTCL patients", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:39:32.610232+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 21, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 20, "name": "Traction", "beatId": "17f2549b-60e8-4ea8-b75d-3f3cfbce32a9", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": null, "evidence": "Traction is highlighted on pages 20-21.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 21, "type": "evidence", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 7, "textChars": 449, "nDataPoints": 1, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:02.612+00", "seconds": 3.256, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/21", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-21", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.25, "x": 0.1, "y": 0.6 }, "kind": "list", "text": "IND open and Phase 3 ready in CTCL", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "27896bf5-171b-41bd-9b28-c28947745e8b", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.37, "y": 0.6 }, "kind": "list", "text": "Use of JAKi in medical dermatology opens up opportunity for indication expansion", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "48e83eb5-0e92-4844-9d5f-83697a3b8405", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.37, "y": 0.3 }, "kind": "list", "text": "Compelling clinical activity observed in cutaneous T cell lymphoma (CTCL) patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "68b6eeae-edc4-408f-9f39-674655341acb", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.1, "y": 0.3 }, "kind": "list", "text": ">100 subjects dosed, demonstrated favorable safety and tolerability", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dc0f0fc7-0e48-4338-be11-688c7967b9a7", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.65, "y": 0.6 }, "kind": "list", "text": "Now in ongoing proof-of-concept study in alopecia areata", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e99c37f8-f495-414b-b748-7e00a7c34667", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.65, "y": 0.3 }, "kind": "list", "text": "Attractive target product profile for the treatment of CTCL patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe27ad09-50e3-4e21-b263-f8cd00fa4b08", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.07 }, "kind": "title", "text": "EQ101: Positive Proof-of-Concept Opens Up Indication Expansion", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a280161-2d4d-46a5-b47e-7119956fbde9", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 21, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 20, "name": "Traction", "beatId": "17f2549b-60e8-4ea8-b75d-3f3cfbce32a9", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": null, "evidence": "Traction is highlighted on pages 20-21.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 22, "type": "resolution", "title": "The slide uses a circular process diagram to show the feedback loop of immune cells and cytokines attacking the hair follicle.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 4, "textChars": 461, "nDataPoints": 0, "notes": "The slide uses a circular process diagram to show the feedback loop of immune cells and cytokines attacking the hair follicle.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:05.613+00", "seconds": 6.25, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/22", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-22", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.94, "x": 0.03, "y": 0.17 }, "kind": "callout", "text": "IL-2, IL-9 and IL-15 are key drivers of disease in alopecia areata, promoting a cycle of increased IFN-γ production and immune cell attack of the hair follicle", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:05.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "42504923-fcc7-437b-8aeb-8fb3a5462f74", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.9, "x": 0.05, "y": 0.35 }, "kind": "diagram", "text": "Circular process diagram showing IL-2, IL-9, IL-15, NK, CD4, CD8, IFN-gamma, and hair follicle interaction", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:05.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7a2d0a68-c31f-4653-adca-246a0e2e1848", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.7, "x": 0.12, "y": 0.96 }, "kind": "source-note", "text": "Xing et al., Nat. Med., 2014; Bertolini et al., PLOS, 2014; Suarez-Farinas et al., J Allergy Clin Immunol, 2015; Dai et al., JCI Insight, 2021", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:05.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c20186b7-7080-43e0-801b-c35effb39842", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.85, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "EQ101: Targeted Treatment Approach for Alopecia Areata", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:05.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "afd32cba-0819-4602-acf9-4606f90ed213", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "4b0c46ba-02d8-4bcc-af78-19eeac821f67", "evidence": "The diagram depicts a self-reinforcing cycle of immune activity.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:23:05.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "frameworkName": "flywheel" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 23, "type": "resolution", "title": "Includes visual longitudinal study (Day 0, 14, 21) and a bar chart comparing efficacy against PBS and Ruxolitinib.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 305, "nDataPoints": 3, "notes": "Includes visual longitudinal study (Day 0, 14, 21) and a bar chart comparing efficacy against PBS and Ruxolitinib.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:02.843+00", "seconds": 3.382, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/23", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-23", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.11, "w": 0.92, "x": 0.04, "y": 0.18 }, "kind": "callout", "text": "EQ101 is more effective than ruxolitinib at hair regrowth and suppression of cytotoxic CD8+ T cells in humanized alopecia model", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.843+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "412c87cc-db13-42cd-af02-570922750662", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.32, "x": 0.62, "y": 0.35 }, "kind": "chart", "text": "EQ101 Reduces CD8+ Cytotoxic T-cell Activation Marker NKG2D", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.843+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5916e189-eb43-47f8-949d-430560bd236c", "parentComponentId": null }, { "bbox": { "h": 0.42, "w": 0.42, "x": 0.14, "y": 0.45 }, "kind": "image", "text": "Longitudinal photos of mice treated with EQ101 and Ruxolitinib", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.843+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b2ba6395-c979-4fbc-84ae-bfa9746a47d5", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.88, "x": 0.04, "y": 0.07 }, "kind": "title", "text": "EQ101 Reverses Immune-Mediated Hair Loss in a Mouse Model", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.843+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c3ec6815-6123-4c56-b5c6-bbe63ca0e88f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "08c5549c-3727-4542-8772-197a37e382ae", "evidence": "Visual comparison of hair growth over time (Day 0 to 21) for two different treatments.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:02.843+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "before-after-framing" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 24, "type": "setup", "title": "The slide compares two different drugs (baricitinib and deuruxolitinib) using two different chart types (line chart with negative values vs line chart with posi", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 5, "textChars": 339, "nDataPoints": 12, "notes": "The slide compares two different drugs (baricitinib and deuruxolitinib) using two different chart types (line chart with negative values vs line chart with positive values) to demonstrate efficacy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:02.619+00", "seconds": 2.974, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/24", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-24", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.45, "x": 0.05, "y": 0.25 }, "kind": "chart", "text": "Baricitinib trial results (BRAVE AA1)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.619+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "23729f30-29c5-4a4a-bc13-60a8d8b3ca2d", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.45, "x": 0.5, "y": 0.25 }, "kind": "chart", "text": "Deuruxolitinib trial results (THRIVE AA1)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.619+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1118174-6caf-45eb-bab1-06e8647fcb1c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.9 }, "kind": "paragraph", "text": "SALT = Severity of Alopecia Tool. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata. Source: Eli Lilly & Concert Pharmaceuticals", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.619+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "24b5224d-b9c8-41c5-93a9-0ca1a8b8dc2e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Alopecia Areata Trials Illustrate Efficacy Bar & Low Placebo Rates", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.619+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d4b60c1-f6a4-41af-9786-cca0504108b0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.1, "y": 0.15 }, "kind": "title", "text": "Percent change from baseline in SALT Score", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.619+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6006797f-1659-4ac0-97f3-ae4cadc17659", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 25, "type": "tension", "title": "Includes a specific callout for a Blackbox warning on existing competitors.", "function": "frame_problem", "rawType": "why_now", "block": null, "metadata": { "slideType": "why_now", "slideTypeCanon": { "name": "Why now", "slug": "why_now", "status": "active", "canonId": "019de52d-0f2e-718d-b8ad-256dd87582d0", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 78, "componentCount": 7, "textChars": 683, "nDataPoints": 4, "notes": "Includes a specific callout for a Blackbox warning on existing competitors.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:03.157+00", "seconds": 3.459, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/25", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-25", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.09, "w": 0.94, "x": 0.03, "y": 0.18 }, "kind": "callout", "text": "EQ101 is positioned as a well-tolerated and effective alternative to JAK inhibitors", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e2c6fda2-a091-4f9d-9257-cb96c51637ec", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.23, "x": 0.51, "y": 0.35 }, "kind": "chart", "text": "I am concerned about the safety of oral JAK inhibitors for my AA patients", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Donut chart", "slug": "donut", "status": "active", "canonId": "019de52d-0006-752c-9528-0fef476b8004", "version": 1, "description": null }, "framework": null }, "subkind": "donut", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "abf07ab1-db9a-4c94-a287-be59ab9bfb64", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.42, "x": 0.05, "y": 0.33 }, "kind": "list", "text": "Currently approved and late-stage pipeline drugs are all JAK inhibitors. There remains a chronic need, without a safe chronic treatment. Dermatologists indicate safety concerns are the primary barriers to JAKi use in AA patients.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2a0c3047-469a-42f0-a69d-c9dd3903bbca", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.42, "x": 0.05, "y": 0.73 }, "kind": "metric", "text": "79% of physicians surveyed, believe there is an extremely high unmet medical need*", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4384ab31-6f5c-45db-8cc7-eebffafdfcab", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.35, "x": 0.12, "y": 0.96 }, "kind": "source-note", "text": "* Spherix Global Insights; ** Olumiant Package Insert", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3f438d4-8323-4a2e-8e31-b1b27ca4edef", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.22, "x": 0.76, "y": 0.33 }, "kind": "table", "text": "Blackbox warning: WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f700de68-8d69-472d-b439-c6b6b57d7af1", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Large Unmet Need in Alopecia Areata", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7203cc49-d2a7-4daf-b40e-3f8994b730da", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 25, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "04b5f862-a1da-427a-9706-844a7a78d8b4", "evidence": "The cost of inaction is implied in the discussion of unmet need.", "position": 1, "objective": "Unmet need in Alopecia Areata", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:39:34.544232+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 26, "type": "resolution", "title": "Includes a timeline-style process diagram for the study phases.", "function": "plan_implementation", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 69, "componentCount": 6, "textChars": 556, "nDataPoints": 5, "notes": "Includes a timeline-style process diagram for the study phases.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:02.411+00", "seconds": 2.675, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/26", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-26", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.4, "x": 0.55, "y": 0.22 }, "kind": "callout", "text": "Target Product Profile: Safer alternative to JAKi with at least comparable efficacy. Patient-administered weekly/bi-weekly subcutaneous injection (similar to DUPIXENT™)", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.411+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6dfa5857-4b12-442c-bee3-6e4f26e4657f", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.46, "x": 0.03, "y": 0.22 }, "kind": "diagram", "text": "Screening (5 weeks) -> Treatment (24 weeks, 2mg/kg IV bolus push) -> Follow-Up (4 weeks)", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.411+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84c5c248-41b1-4a8e-bf9e-2b30d0bdb459", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.22, "x": 0.05, "y": 0.63 }, "kind": "paragraph", "text": "Population N=30: At least 35% scalp hair loss, as defined by a SALT score ≥35. Current episode of hair loss lasting >6 months to <7 years.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.411+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "45087ef6-bafb-4779-95c5-77ead031bd5c", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.18, "x": 0.32, "y": 0.63 }, "kind": "paragraph", "text": "Study Objectives: Efficacy, Safety & tolerability, PK/PD and biomarkers", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.411+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7c828b10-8a50-42e9-8d88-7a0f19dba532", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.12, "y": 0.96 }, "kind": "source-note", "text": "SALT = Severity of Alopecia Tool", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.411+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee1c8320-22ac-4ac4-a3fe-5e6a6c89f549", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.88, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Phase 2 Study of EQ101 in Adults With Moderate to Severe AA", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:02.411+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "988c8137-b629-44d1-bc9d-890c99d88f89", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "0e0c814a-3d66-4b65-b5e0-752cfdfc0aa8", "evidence": "Study design timeline", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:23:02.411+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "frameworkName": "process" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 27, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 6, "componentCount": 2, "textChars": 68, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:01.66+00", "seconds": 1.838, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/27", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-27", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.052, "w": 0.118, "x": 0.851, "y": 0.068 }, "kind": "image", "text": "equillium", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9d589ad-d5b4-460e-b1c2-c6c1515a32e4", "parentComponentId": null }, { "bbox": { "h": 0.136, "w": 0.44, "x": 0.048, "y": 0.444 }, "kind": "title", "text": "EQ102 First-in-Class Bi-specific Inhibitor of IL-15 & IL-21", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:01.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "944d7143-0af9-411b-9714-0faedcb874d0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 28, "type": "resolution", "title": "The slide uses a four-column layout to explain the target, the molecule structure, the mechanism of action, and the current clinical status.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 74, "componentCount": 7, "textChars": 930, "nDataPoints": 0, "notes": "The slide uses a four-column layout to explain the target, the molecule structure, the mechanism of action, and the current clinical status.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:04.73+00", "seconds": 4.906, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/28", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-28", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.21 }, "kind": "callout", "text": "IL-15 & IL-21 are key cytokines driving GI inflammation in celiac disease and IBD", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.73+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d3c0129d-3f90-460a-aa1e-ca15cc47a244", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.75, "x": 0.12, "y": 0.94 }, "kind": "disclaimer", "text": "GI = gastrointestinal; IBD = inflammatory bowel disease; CeD = celiac disease; SAD = single ascending dose; MAD = multiple ascending dose\n1) Sarra et al., Mucosal Immunol, 2013; 2) Kooy-Winkelaar et al., Gut, 2016; 3) Ciszewski et al., Gastroenterology, 2020", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.73+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3ccdae5-15b4-480c-9fbe-6aaa5f995de0", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.22, "x": 0.03, "y": 0.54 }, "kind": "list", "text": "Natural biological synergy of IL-15 and IL-21 (T and B cell biology)\nIL-15 a validated target in the treatment of celiac disease", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.73+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10a7bfae-8c40-4b6a-bcc6-a4d9bf393619", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.22, "x": 0.53, "y": 0.54 }, "kind": "list", "text": "Inhibits the IL-15 & IL-21 induced signaling pathways in CeD patient-derived T cells organoid cultures that are key for tissue destruction\nPrevents intestinal tissue damage in a humanized mouse model of GI inflammation", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.73+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "91d17d76-9056-41a3-8196-1f607a23468b", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.22, "x": 0.28, "y": 0.54 }, "kind": "list", "text": "PEGylated peptide based on the D-helix of γc cytokines selectively inhibiting IL-15 & IL-21 signaling\nAdministered as subcutaneous injection", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.73+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aebb82ef-4826-423c-9cf1-cb74e0b74ea1", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.18, "x": 0.78, "y": 0.54 }, "kind": "list", "text": "Currently in a Phase 1 first-in-human SAD/MAD study", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.73+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cbff53ae-3924-4a8d-8247-1587d3b127ec", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "EQ102: A First-in-class Bi-Specific Cytokine Inhibitor", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.73+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aefe9e82-519d-4042-acbf-8a74b5917bfb", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 29, "type": "tension", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 83, "componentCount": 9, "textChars": 654, "nDataPoints": 2, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:03.54+00", "seconds": 2.987, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/29", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-29", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.35, "x": 0.0058, "y": 0.0055 }, "kind": "callout", "text": "Multi-Billion Dollar Annual market opportunity", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bdded6cf-d7b2-4c2c-8ad5-9e419bd17b08", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.9, "x": 0.03, "y": 0.0025 }, "kind": "list", "text": "Autoimmune disease triggered by consuming gluten resulting in damage to GI tract\nSymptoms include vomiting, diarrhea, abdominal pain, anemia and fatigue\nMany patients non-responsive to strict gluten free diet, experiencing ongoing GI inflammation\nUnresolved inflammation leads to malnutrition, other autoimmune conditions & GI cancers", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8239de04-e944-4cfd-a32f-81a52c675997", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.03, "y": 0.006 }, "kind": "metric", "text": ">750,000", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad7cce85-491b-4941-b247-0faae5105d06", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.1, "x": 0.35, "y": 0.006 }, "kind": "metric", "text": "0", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dc1172f3-ad68-47b7-975e-19a94ba6e2a4", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.1, "x": 0.35, "y": 0.0072 }, "kind": "paragraph", "text": "Approved Drugs", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "063b43cc-e899-49b0-9bd7-9c57dd4f7dca", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.03, "y": 0.0072 }, "kind": "paragraph", "text": "Non-responsive celiac disease patients in the United States", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "175ea963-06e0-4948-827b-194a552a62ec", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.12, "y": 0.0092 }, "kind": "source-note", "text": "GI = gastrointestinal\n1) Beyond Celiac Website\n2) Lebwohl et al., Aliment Pharmacol. Ther. 2014 March ; 39(5): 488–495", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "48db5e50-c24c-4fa0-9880-627d3f32ed42", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.9, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "EQ102 Opportunity: Celiac Disease has no Approved Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d81ee994-f577-4440-b488-5d4e068b5b9b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.03, "y": 0.0019 }, "kind": "title", "text": "Celiac Disease:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e932f15a-3e75-43db-a728-19b0e7eae5c8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 30, "type": "tension", "title": "Includes a biological process diagram and a gene expression heatmap.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 5, "textChars": 573, "nDataPoints": 0, "notes": "Includes a biological process diagram and a gene expression heatmap.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:04.222+00", "seconds": 3.631, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/30", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-30", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.11, "w": 0.94, "x": 0.03, "y": 0.18 }, "kind": "callout", "text": "Elevated levels of IL-15 & IL-21 synergistically drive inflammatory T and B cell responses culminating in tissue damage in celiac patients", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.222+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3acc5df7-dc71-4280-80f2-5588d72279e4", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.65, "y": 0.35 }, "kind": "chart", "text": "Unique gene expression profiles elicited by IL-15 and IL-15 + IL-21 in gut intra-epithelial lymphocytes from CeD patients", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Heatmap", "slug": "heatmap", "status": "active", "canonId": "019de52d-00cd-71ee-bf36-233b7817c304", "version": 1, "description": null }, "framework": null }, "subkind": "heatmap", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.222+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "47aab3ff-9c11-4e2a-a664-52f1cc772dce", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.6, "x": 0.03, "y": 0.35 }, "kind": "diagram", "text": "Biological pathway from healthy epithelium to cell death via IL-15/IL-21", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.222+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2df91edd-25b2-45eb-9196-0f5e0b54a5d1", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.12, "y": 0.95 }, "kind": "source-note", "text": "Ciszewski et al., Gastroenterology, 2020; Frohna et al., 17th International Celiac Disease Symposium, New Delhi, 2017. CeD = celiac disease; IE-CTL = intraepithelial cytotoxic T lymphocyte", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.222+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7541b680-50cf-49ff-ad8b-a159fd4560da", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Celiac Disease: Destructive Immune-mediated GI Disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.222+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0cde8c4d-d2c3-4469-af3c-68319ffb04f7", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "45af66c1-ca95-454a-921b-b72bfbae162b", "evidence": "Biological pathway from healthy epithelium to cell death via IL-15/IL-21", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:36:13.085197+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 31, "type": "resolution", "title": "The slide uses a biological pathway diagram and a bar chart to demonstrate efficacy.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 5, "textChars": 460, "nDataPoints": 5, "notes": "The slide uses a biological pathway diagram and a bar chart to demonstrate efficacy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:07.09+00", "seconds": 6.304, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/31", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-31", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.11, "w": 0.94, "x": 0.03, "y": 0.17 }, "kind": "callout", "text": "EQ102 inhibits IL-15 & IL-21 synergism activating pathogenic pathways that cause tissue damage and thus can maintain healthy gut epithelium", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:07.09+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "df06d4ea-7981-4aa8-8db0-cb10843d527a", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.65, "y": 0.33 }, "kind": "chart", "text": "Inhibition of Granzyme B expression in CeD IE-CTLs stimulated with IL-15 & IL-21", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:07.09+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bdccee67-30f3-4da6-a6e4-c5d1bbbde493", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.6, "x": 0.03, "y": 0.35 }, "kind": "diagram", "text": "Mechanism of action diagram showing EQ102 blocking IL-15/IL-21 pathways", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:07.09+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a661b445-9888-4eef-b713-6df17f70beb4", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.12, "y": 0.95 }, "kind": "source-note", "text": "Ciszewski et al., Gastroenterology, 2020; Frohna et al., 17th International Celiac Disease Symposium, New Delhi, 2017", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:07.09+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8322575-8361-4ace-aac1-274a035b58dd", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "EQ102: Targeted Treatment Approach for Celiac Disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:07.09+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a95f4b0-2893-4d7a-ae45-ddcd2851109f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 32, "type": "setup", "title": "The slide uses a process-like diagram to show treatment approaches and highlights the specific mechanism of action (IL-15/IL-21 inhibition) as a superior strate", "function": "argue_timing", "rawType": "why_now", "block": null, "metadata": { "slideType": "why_now", "slideTypeCanon": { "name": "Why now", "slug": "why_now", "status": "active", "canonId": "019de52d-0f2e-718d-b8ad-256dd87582d0", "version": 1, "description": null }, "function": "argue_timing", "functionCanon": { "name": "Argue timing (why now)", "slug": "argue_timing", "status": "active", "canonId": "019de52d-16f8-74de-9ec2-900be07d90dd", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 8, "textChars": 755, "nDataPoints": 0, "notes": "The slide uses a process-like diagram to show treatment approaches and highlights the specific mechanism of action (IL-15/IL-21 inhibition) as a superior strategy.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:08.56+00", "seconds": 7.772, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/32", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-32", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.65, "x": 0.03, "y": 0.18 }, "kind": "callout", "text": "Potential to be a differentiated asset in celiac disease addressing both key inflammatory drivers: IL-15 and IL-21", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:08.56+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c90f67b0-85a9-4493-a420-7bd430090eb1", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.65, "x": 0.03, "y": 0.035 }, "kind": "diagram", "text": "Approaches to Treating Celiac Disease: gluten modification, restore gut barrier function, promote immune tolerance, reduce inflammation (IL-15/IL-21)", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:08.56+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3e29d08c-cc9e-46d9-8954-b1e9223fbe6a", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.7, "y": 0.8 }, "kind": "disclaimer", "text": "FDA guidance was recently updated and provides clear guidelines for path to approval. Emphasis has been placed on development of effective anti-inflammatory strategies.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:08.56+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "647f6530-52b0-4d1a-b5d6-912a13d9fedf", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.7, "y": 0.5 }, "kind": "image", "text": "Takeda, Pfizer, Anokion, ProventionBio", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:08.56+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b8f9ed52-da59-4724-b901-670807e3570b", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.25, "y": 0.75 }, "kind": "paragraph", "text": "IL-15 inhibition alone has shown efficacy in celiac disease, but results suggest that dual inhibition of IL-15 and IL-21 may have superior effect.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:08.56+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "65bd6083-816a-49a3-b79f-ed532692869c", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.12, "y": 0.96 }, "kind": "source-note", "text": "https://www.fda.gov/media/157682/download", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:08.56+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a43a884b-6a32-44fb-95ab-e3d4731ad6f8", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.7, "y": 0.035 }, "kind": "title", "text": "Increasing Regulatory Clarity and Strategic Interest in Celiac Disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:08.56+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c0ae035-3ef9-4fd7-a0ef-e43a7a663e2e", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.45, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Opportunity in Celiac Disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:08.56+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "47b138aa-1fa3-4077-8c00-4ee4b25528cc", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "SCQA Framework", "slug": "scqa-framework", "status": "active", "bestFor": null, "canonId": "019dd956-7bcb-763f-bdf6-1dfedf3bd36c", "version": 1, "bodyDocId": "019df22a-a0b0-719e-937e-2ac31e53d32c", "description": "Situation, Complication, Question, Answer - structured problem framing", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "07f938dd-509c-4c83-9de5-37f99c94325a", "evidence": "Approaches to Treating Celiac Disease: gluten modification, restore gut barrier function, promote immune tolerance, reduce inflammation (IL-15/IL-21)", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:36:13.215947+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 33, "type": "resolution", "title": "The slide outlines a sequential clinical trial process.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 7, "textChars": 574, "nDataPoints": 0, "notes": "The slide outlines a sequential clinical trial process.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:04.734+00", "seconds": 3.897, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/33", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-33", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.9, "x": 0.05, "y": 0.385 }, "kind": "diagram", "text": "Single Ascending Dose -> Multiple Ascending Dose -> Proof-of-Concept Study in Celiac Disease Patients", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1a225686-8615-428a-8ddd-ac328f09653a", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.68, "y": 0.65 }, "kind": "list", "text": "Objective Celiac Disease Patients: Efficacy signal in patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2e651014-aaea-4012-8b02-0d73a8e7484e", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.35, "y": 0.65 }, "kind": "list", "text": "Secondary Objectives SAD & MAD: pharmacokinetics (PK) and pharmacodynamics (PD) of EQ102", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3fca9a48-90dd-45dd-b2ac-6633867d9976", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.05, "y": 0.65 }, "kind": "list", "text": "Primary Objective SAD & MAD: safety and tolerability of EQ102 after single and multiple ascending doses", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a82c0f2-bf05-4151-ab13-83c347292b51", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.75, "x": 0.03, "y": 0.18 }, "kind": "paragraph", "text": "Randomized, double-blinded, controlled SAD/MAD study, followed by proof-of-concept evaluation in patients with celiac disease", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c553ac36-af31-4f71-8c9d-8457000bf613", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.12, "y": 0.94 }, "kind": "source-note", "text": "SAD = single ascending dose; MAD = multiple ascending dose", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "56b81a4f-c9ce-4734-981d-58c5c4b9fae6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.55, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Phase 1 First-in-Human Study of EQ102", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "20c377b4-0491-4a68-943c-3c2e9d494158", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "26a6adcb-c82b-470b-a80f-6a49eab61bdf", "evidence": "Sequential flow of clinical trial phases", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:23:04.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "frameworkName": "process" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 34, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 3, "componentCount": 2, "textChars": 18, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:03.335+00", "seconds": 2.412, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/34", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-34", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.048, "w": 0.118, "x": 0.851, "y": 0.068 }, "kind": "image", "text": "equillium", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "08948ba3-63dd-458f-8061-68cca3c84cd5", "parentComponentId": null }, { "bbox": { "h": 0.053, "w": 0.178, "x": 0.113, "y": 0.443 }, "kind": "title", "text": "Corporate", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "08f5a0d9-06f4-4038-92e0-ba5cfd79b5b5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 35, "type": "setup", "title": "The slide highlights the team's pedigree by listing past company affiliations for each executive and providing a collective logo grid at the bottom.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 10, "textChars": 164, "nDataPoints": 0, "notes": "The slide highlights the team's pedigree by listing past company affiliations for each executive and providing a collective logo grid at the bottom.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:04.781+00", "seconds": 3.748, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/35", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-35", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.165, "w": 0.165, "x": 0.645, "y": 0.208 }, "kind": "image", "text": "Christine Zedelmayer", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.781+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f7a90b6-3a31-4d4e-94c2-7364c03e853d", "parentComponentId": null }, { "bbox": { "h": 0.165, "w": 0.165, "x": 0.485, "y": 0.45 }, "kind": "image", "text": "Maple Fung", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.781+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4879d087-59c5-4fb2-ba7f-c45bf2a47f7c", "parentComponentId": null }, { "bbox": { "h": 0.165, "w": 0.165, "x": 0.025, "y": 0.45 }, "kind": "image", "text": "Jason Keyes", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.781+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "727ec120-cca5-4195-890f-a7d87e57e36b", "parentComponentId": null }, { "bbox": { "h": 0.165, "w": 0.165, "x": 0.245, "y": 0.45 }, "kind": "image", "text": "Joel Rothman", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.781+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7488a63e-6471-4594-b001-3097bb3d29ee", "parentComponentId": null }, { "bbox": { "h": 0.165, "w": 0.165, "x": 0.745, "y": 0.45 }, "kind": "image", "text": "Matt Ritter", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.781+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7501bb42-31bf-4e38-b263-7c0f2677df3f", "parentComponentId": null }, { "bbox": { "h": 0.165, "w": 0.165, "x": 0.105, "y": 0.208 }, "kind": "image", "text": "Bruce Steel", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.781+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "815ca2e3-2229-4ab5-b1ce-564922eecb98", "parentComponentId": null }, { "bbox": { "h": 0.165, "w": 0.165, "x": 0.35, "y": 0.208 }, "kind": "image", "text": "Steve Connelly", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.781+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce7301c7-d93a-4051-a855-ed8463461383", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.925, "x": 0.037, "y": 0.775 }, "kind": "image", "text": "Company logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.781+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7949bc08-7014-4671-b6ab-cd959fb5106e", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.415, "x": 0.037, "y": 0.078 }, "kind": "title", "text": "Accomplished Executive Leadership", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.781+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7931c978-1df3-4dd7-879b-4e4093f8c63e", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.288, "x": 0.037, "y": 0.72 }, "kind": "title", "text": "Extensive Industry Experience", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.781+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b27556d7-92b6-48fa-ace2-b858a5fd3d39", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 35, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 35, "name": "Team", "beatId": "493482e1-fe58-4e6b-904e-a76e5407321c", "matchId": "f6365c0d-495a-4dfd-aaa7-9a548c10a65c", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "The team is introduced on page 35.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 36, "type": "appendix", "title": "The slide uses a timeline framework to map patent coverage and exclusivity periods across two main product categories.", "function": "other", "rawType": "appendix", "block": null, "metadata": { "slideType": "appendix", "slideTypeCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-0762-71f8-b564-89ab863301cc", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 6, "textChars": 479, "nDataPoints": 10, "notes": "The slide uses a timeline framework to map patent coverage and exclusivity periods across two main product categories.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:03.821+00", "seconds": 2.722, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/36", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-36", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.78, "x": 0.185, "y": 0.16 }, "kind": "chart", "text": "Timeline of patent and exclusivity coverage from 2006 to 2044", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a685c69-7b80-4ede-a40f-cc1ded41f74e", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.35, "x": 0.16, "y": 0.91 }, "kind": "disclaimer", "text": "Assumptions: Listed applications will issue; Biologics Exclusivity will be granted and will begin at NDA approval; Potential patent term extensions not shown", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5704ee07-83c5-4743-8612-d172f2003419", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.12, "x": 0.036, "y": 0.81 }, "kind": "legend", "text": "Biocon Filings (Blue), EQ Filings (Green)", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ed3e2956-49e2-47b3-b597-17f9be89373d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.18, "x": 0.036, "y": 0.26 }, "kind": "list", "text": "Multi-Cytokine Technologies: 6 patent families, 33 issued patents, 44 applications pending", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e8e0d454-4e1a-430a-a060-8b94e958a70a", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.18, "x": 0.036, "y": 0.69 }, "kind": "list", "text": "Itolizumab: 11 patent families, 26 issued patents, 31 applications pending", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fef45665-9030-4385-ab79-87e41c99b298", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.53, "x": 0.036, "y": 0.075 }, "kind": "title", "text": "Equillium Intellectual Property & Regulatory Exclusivity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:03.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a855451-8c61-419a-a5b4-6fda2af4b1b0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "6b543cfe-ee0a-4429-861d-9a615156728d", "evidence": "Timeline visualization of overlapping patent and exclusivity periods", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:23:03.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 37, "type": "setup", "title": "The slide provides a snapshot of the company's financial health as of late 2023.", "function": "summarize", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 5, "textChars": 502, "nDataPoints": 4, "notes": "The slide provides a snapshot of the company's financial health as of late 2023.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:04.706+00", "seconds": 3.278, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/37", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-37", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.48, "w": 0.317, "x": 0.646, "y": 0.275 }, "kind": "callout", "text": "Well capitalized to reach multiple milestones Lean operating model and disciplined spending Cash runway expected to extend into 2025", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f8fb363-b6bb-426e-9a6c-a1a8f7f4f753", "parentComponentId": null }, { "bbox": { "h": 0.055, "w": 0.501, "x": 0.037, "y": 0.8 }, "kind": "disclaimer", "text": "Please refer to the Form 10-Q filed on November 8, 2023 for complete financials of the company as of September 30, 2023", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "261e415f-d037-40f0-92e2-05ac0308eefd", "parentComponentId": null }, { "bbox": { "h": 0.415, "w": 0.601, "x": 0.037, "y": 0.307 }, "kind": "table", "text": "Total Cash and Investments (as of September 30, 2023) $46.3M Q3 2023: Net Cash Used in Operations $1.9M Shares Outstanding (as of November 6, 2023) 35.1M Market Cap (as of close November 8, 2023) $17.9M", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "KPI table", "slug": "kpi", "status": "active", "canonId": "019de52d-0324-7799-a84e-d0885a8ad400", "version": 1, "description": null }, "framework": null }, "subkind": "kpi", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1d76954a-fe6e-4eaa-a6bb-ed295173729f", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.425, "x": 0.037, "y": 0.075 }, "kind": "title", "text": "Equillium Financial Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "39a573d3-7313-4d83-bed1-57851c223103", "parentComponentId": null }, { "bbox": { "h": 0.032, "w": 0.243, "x": 0.037, "y": 0.235 }, "kind": "title", "text": "Key Financial Metrics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f0159e6-456f-4b71-9e06-550998d71bec", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 38, "type": "resolution", "title": "The slide uses a grouped list format to present clinical trial milestones.", "function": "plan_implementation", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 49, "componentCount": 4, "textChars": 692, "nDataPoints": 0, "notes": "The slide uses a grouped list format to present clinical trial milestones.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:04.915+00", "seconds": 3.483, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/38", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-38", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.135, "w": 1, "x": 0, "y": 0.745 }, "kind": "callout", "text": "Cash runway expected to extend into 2025*. Potential Ono Exercise Payment of ~$33M** would significantly extend cash runway", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.915+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee01e8d1-f459-495d-a0f6-d272d1f341d1", "parentComponentId": null }, { "bbox": { "h": 0.48, "w": 0.926, "x": 0.037, "y": 0.22 }, "kind": "list", "text": "EQ101 – Phase 2 Clinical Study: Alopecia Areata – Initial Data (Q4 2023), Alopecia Areata – Topline Data (Mid-2024). EQ102 – Phase 1 Clinical Study: SAD / MAD (healthy volunteers) – Data (Q4 2023), Celiac Disease – Data (2024). Itolizumab – Phase 1b / Phase 3 Clinical Studies: Lupus Nephritis EQUALISE Study (Phase 1b) – Topline Data (Early 2024), aGVHD EQUATOR Study (Phase 3) – Interim Review (2024).", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.915+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f185bc9a-eef3-4432-b7be-40cdbd34b124", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.737, "x": 0.163, "y": 0.965 }, "kind": "source-note", "text": "* Estimated based on current operating plan ** Option exercise payment of ¥5.0B is based in JPY and subject to currency exchange rate at the time of payment", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.915+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae5e02ae-dd38-450b-8c3e-611f86214849", "parentComponentId": null }, { "bbox": { "h": 0.048, "w": 0.178, "x": 0.037, "y": 0.075 }, "kind": "title", "text": "Milestones", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.915+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "53d40daa-5ed8-4a91-adbd-e457454f4344", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "90d482f5-91f1-44d5-a093-41850816053a", "evidence": "The slide presents a timeline of clinical milestones for multiple programs.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 11:23:04.915+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 39, "type": "setup", "function": "state_next_steps", "rawType": "closing_ask", "block": null, "metadata": { "slideType": "closing_ask", "slideTypeCanon": { "name": "Closing ask", "slug": "closing_ask", "status": "active", "canonId": "019de52d-0aa4-750f-8aa1-8d622dd99f5c", "version": 1, "description": null }, "function": "state_next_steps", "functionCanon": { "name": "State next steps", "slug": "state_next_steps", "status": "active", "canonId": "019de52d-14ca-70ac-b534-971f458cdf29", "version": 1, "description": null }, "density": "sparse", "densityScore": 9, "componentCount": 3, "textChars": 29, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:23:04.076+00", "seconds": 2.437, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-341d-707d-8f10-e094a3d9771c/39", "deck": "/decks/019de076-341d-707d-8f10-e094a3d9771c", "deckAnchor": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-39", "deckJson": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.35, "x": 0.07, "y": 0.145 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.076+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "db5b4046-57fa-4c73-b7ad-afd260ed582c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.5, "y": 0.8 }, "kind": "paragraph", "text": "www.equilliumbio.com", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.076+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84ae4a84-6fe0-4e79-8fce-c1615db932f5", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.5, "y": 0.5 }, "kind": "title", "text": "Thank you", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:23:04.076+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "29e3cf40-fa44-44c6-9fea-80546740a238", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Closing ask", "slug": "closing-ask-slide", "status": "active", "bestFor": null, "canonId": "019df269-295e-70bc-9ee8-baa90a49922d", "version": 1, "bodyDocId": "019df269-293a-7523-9bb5-2692a9047168", "description": "The last slide the reader sees. Treat it as a single design moment —", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "3a1ed35c-9f03-489e-bd4c-a915de6fc377", "evidence": "paragraph/paragraph: www.equilliumbio.com", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:36:13.567183+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 10, "to": 10, "label": "Problem", "description": "The problem is clearly stated on page 10." }, { "from": 5, "to": 9, "label": "Solution", "description": "The solution is presented on pages 5-9." }, { "from": 18, "to": 18, "label": "Market Size", "description": "Market sizing is discussed on page 18." }, { "from": 20, "to": 21, "label": "Traction", "description": "Traction is highlighted on pages 20-21." }, { "from": 35, "to": 35, "label": "Team", "description": "The team is introduced on page 35." } ], "loops": [ { "from": 3, "to": 5, "label": "Golden Circle", "description": "Why Equillium" }, { "from": 25, "to": 25, "label": "Cost Of Inaction", "description": "Unmet need in Alopecia Areata" } ] }